dc.contributor.author | Shahzadi, Irum | |
dc.contributor.author | Parveen, Bushra | |
dc.contributor.author | Ahmad, Sajjad | |
dc.contributor.author | Khan, Samreen Gul | |
dc.contributor.author | Zahoor, Ameer Fawad | |
dc.contributor.author | Rasul, Azhar | |
dc.contributor.author | Zahid, Faisal Maqbool | |
dc.date.accessioned | 2022-12-07T04:34:48Z | |
dc.date.available | 2022-12-07T04:34:48Z | |
dc.date.issued | 2022-05-03 | |
dc.identifier.citation | Shahzadi, I., Parveen, B., Ahmad, S., Zahoor, A. F., Rasul, A., & Zahid, F. M. (2022). In-vitro cytotoxic evaluation, hemolytic and thrombolytic potential of newly designed acefylline based hydrazones as potent anticancer agents against human lung cancer cell line (A549). Pakistan Journal of Pharmaceutical Sciences, 35(3 (Special)), 885-889. | en_US |
dc.identifier.issn | 1011-601X | |
dc.identifier.uri | http://142.54.178.187:9060/xmlui/handle/123456789/14802 | |
dc.description.abstract | Hydrazones of theophylline-7-acetic acid 5a-g have been synthesized using ultrasonic irradiation as well as conventional heating system and analyzed for their anticancer characteristics against human lung cancer cell line (A549). Compound 5g with cell viability 33.19±0.49% (100 μg/μL) compared to the starting reference drug acefylline having cell viability 86.32±11.75% (100 μg/μL) was found to be the most active anticancer agent among all. The synthesized derivatives were also exposed to hemolytic and thrombolytic studies to determine their cytotoxic profile and results revealed their low toxicity and moderate clot lysis activity. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Karachi: Pakistan Journal of Botany, Botanical Garden, University of Karachi | en_US |
dc.subject | Hydrazones | en_US |
dc.subject | acefylline | en_US |
dc.subject | cell viability | en_US |
dc.subject | hemolytic | en_US |
dc.subject | thrombolytic | en_US |
dc.title | In-vitro cytotoxic evaluation, hemolytic and thrombolytic potential of newly designed acefylline based hydrazones as potent anticancer agents against human lung cancer cell line (A549) | en_US |
dc.type | Article | en_US |